BREAKING: Tandem Diabetes shares surge 30% above IPO price

November 14, 2013 by Brad Perriello

Shares of Tandem Diabetes Care gain on the launch of its initial public offering, with shares opening at $19.40 apiece, nearly 30% ahead of the price Tandem set yesterday.

BREAKING: Tandem Diabetes shares surge 30% above IPO price

Shares of Tandem Diabetes Care (NSDQ:TNDM) are up some 30% today after the medical device company's initial public offering debuted on the NASDAQ exchange.

TNDM shares opened and $19.40 apiece, 29.3% ahead of the $15-per-share price Tandem assigned yesterday, peaking at $20.20 before subsiding to $19.35 as of about 10:40 a.m.

That sets Tandem up to raise more that the $120 million pricing; if it were to sell all 8 million shares at the $19.40 price the IPO would raise more than $155 million. And that doesn't account for a 1.2 million-share over-allotment for the offering's underwriters, which if exercised would push the raise even higher. Shares are expected to begin trading today under the TNDM symbol.

Sign up to get our free newsletters delivered straight to your inbox

San Diego-based Tandem said the offering is expected to run until Nov. 19. The company, which makes the the touch-screen t:slim insulin delivery system, 1st estimated that the offering would raise $120 million when it filed for the IPO last month.